Mount Yale Investment Advisors LLC Sells 7,208 Shares of Abbott Laboratories (NYSE:ABT)
Mount Yale Investment Advisors LLC trimmed its position in shares of Abbott Laboratories (NYSE:ABT – Get Rating) by 30.6% during the third quarter, according to the company in its most recent Form 1
Abbott Laboratories (NYSE:ABT) Updates FY23 Earnings Guidance
Abbott Laboratories (NYSE:ABT – Get Rating) updated its FY23 earnings guidance on Wednesday. The company provided earnings per share guidance of $4.30-4.50 for the period, compared to the consensus e
Is Abbott Laboratories a Good Dividend Stock to Buy Now?
Research Analysts Issue Forecasts for Abbott Laboratories' Q1 2023 Earnings (NYSE:ABT)
Abbott Laboratories (NYSE:ABT – Get Rating) – William Blair cut their Q1 2023 EPS estimates for shares of Abbott Laboratories in a report released on Thursday, January 26th. William Blair analyst
Abbott Labs (ABT) Gets a Buy From RBC Capital
Abbott Laboratories Stock Underperforms Friday When Compared To Competitors
This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Abbott Laboratories (ABT) slid 1.01% to $109.95 Friday, on what proved to be an all-around
Abbott Laboratories (NYSE:ABT) Posts Quarterly Earnings Results, Beats Expectations By $0.13 EPS
Abbott Laboratories (NYSE:ABT – Get Rating) released its quarterly earnings data on Wednesday. The healthcare product maker reported $1.03 earnings per share (EPS) for the quarter, beating the consen
Abbott Labs Price Target Raised to $125.00/Share From $122.00 by Barclays
Abbott Labs Is Maintained at Overweight by Barclays
Abbott Labs Is Maintained at Overweight by Barclays
Barclays Maintains Overweight on Abbott Laboratories, Raises Price Target to $125
Barclays analyst Matt Miksic maintains Abbott Laboratories (NYSE:ABT) with a Overweight and raises the price target from $122 to $125.
Loading...
No Stock Yet